Gastric cancer risk assessment based on serum pepsinogen
- VernacularTitle:Ходоодны хорт хавдрын эрсдлийг ийлдсийн пепсиногенд тулгуурлан үнэлэх нь
- Author:
Ganchimeg D
1
;
Bayarmaa N
2
;
Tegshjargal B
3
;
Batbold B
3
;
Erkhembulgan P
3
;
Sodnomtsogt L
3
;
Tulgaa L
3
Author Information
1. School of Medicine, Mongolian National University of Medical Sciences;Institute of Medical Sciences, Mongolian National University of Medical Sciences
2. School of Medicine, Mongolian National University of Medical Sciences
3. Institute of Medical Sciences, Mongolian National University of Medical Sciences
- Publication Type:Journal Article
- Keywords:
biological marker;
cancer screening;
atrophic gastritis;
screening test;
stomach neoplasm
- From:Mongolian Medical Sciences
2023;203(1):8-16
- CountryMongolia
- Language:Mongolian
-
Abstract:
Introduction:Cases of gastric cancer have been declining worldwide in recent years. However, gastric cancer incidence increased in the last decade in Mongolia. In Mongolia, over 80% of gastric cancer cases are diagnosed during the late stage. Several studies have revealed that serum pepsinogens (PGs) level reflects, indirectly, histological and functional characteristics of the gastric mucosa.
Goal:We aimed to evaluate the risk of gastric cancer and its precancerous condition based on serum PGI, PGI/II biomarkers.
Materials and Methods:This case-control study enrolled 114 subjects, including patients with gastric cancer (n=36), atrophic gastritis (n=40) and healthy controls (n=138). The questionnaires were obtained to determine risk factors. Serum PGI, PGII, and H. pylori IgG levels were measured by ELISA (Pepsinogen I ELISA; Pepsinogen II ELISA; H.Pylori IgG ELISA; BIOHIT Plc, Helsinki, Finland). PGI to PGII ratio was calculated. Patients were classified into the ABC(D) group according to Miki K approach. Also, we developed new scoring system based on some risk factors and serum PGI, PGI/II ratio. Logistic regressions were performed to evaluate risk and expressed by odds ratio (OR) and 95% confidence intervals (95%CI).
Results:Mean age of the subjects was 60±10.9 years. H.Pylori was positive in 67 subjects. The serum PGI and PGI/II ratio levels were significantly decreased in gastric cancer and atrophic gastritis groups compared to the healthy control. According to classification ABC(D), group D (OR 5.04, 95% CI 1.13-22.50) had higher proportion of atrophic gastritis cases, group C (OR 6.19, 95% CI 1.04-36.78) had higher proportion of gastric cancer cases than others. Additionally, we created a risk prediction scoring system with a score ranging from 0 to 7, based on variables age, family history of gastric cancer, prior disease history, PGI and PGI/II ratio levels. For the atrophic gastritis patients, 17 (42.5%) were classified into medium-risk category (OR 4.49, 95% CI 1.38-14.58) and 17 (42.5%) were classified into high-risk category (OR 7.69, 95% CI 2.16-27.43). Whereas, 11 (30.6%) patients with gastric cancer were classified into medium-risk category (OR 4.35, 95% CI 1.13-16.85), 21 (58.3%) were classified into high-risk category (OR 14.25, 95% CI 3.60-56.43).
Conclusion:The methods based on serum PGI and PGI/II may identify a high risk population of gastric cancer and atrophic gastritis.
- Full text:2023-203(1)8-16.pdf
